{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:40:22Z","timestamp":1761183622717,"version":"build-2065373602"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T00:00:00Z","timestamp":1629936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004014","name":"Japan IDDM network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004014","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["2618K16225"],"award-info":[{"award-number":["2618K16225"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jphs.2021.08.010","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T23:06:31Z","timestamp":1630710391000},"page":"340-347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Peripheral combination treatment of leptin and an SGLT2 inhibitor improved glucose metabolism in insulin-dependent diabetes mellitus mice"],"prefix":"10.1016","volume":"147","author":[{"given":"Hiroshi","family":"Yaginuma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoichi","family":"Banno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Runan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keigo","family":"Taki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Mizoguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Tsunekawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Onoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Iwama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetaka","family":"Suga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Arima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jphs.2021.08.010_bib1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/1479164114561992","article-title":"Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences","volume":"12","author":"Gallo","year":"2015","journal-title":"Diabetes Vasc Dis Res"},{"issue":"1","key":"10.1016\/j.jphs.2021.08.010_bib2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","article-title":"The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus","volume":"66","author":"Vallon","year":"2015","journal-title":"Annu Rev Med"},{"issue":"1","key":"10.1016\/j.jphs.2021.08.010_bib3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.12.027","article-title":"Renoprotective effects of sodium-glucose cotransporter-2 inhibitors","volume":"94","author":"Heerspink","year":"2018","journal-title":"Kidney Int"},{"issue":"16","key":"10.1016\/j.jphs.2021.08.010_bib4","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.3390\/ijerph16162965","article-title":"SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects","volume":"16","author":"Tentolouris","year":"2019","journal-title":"Int J Environ Res Publ Health"},{"issue":"22","key":"10.1016\/j.jphs.2021.08.010_bib5","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.jphs.2021.08.010_bib6","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.jphs.2021.08.010_bib7","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.jphs.2021.08.010_bib8","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS program randomised clinical trials","volume":"6","author":"Perkovic","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.jphs.2021.08.010_bib9","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.jphs.2021.08.010_bib10","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"10.1016\/j.jphs.2021.08.010_bib11","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.jphs.2021.08.010_bib12","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/jphp.12223","article-title":"Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats","volume":"66","author":"Tahara","year":"2014","journal-title":"J\u00a0Pharm Pharmacol"},{"key":"10.1016\/j.jphs.2021.08.010_bib13","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fcvm.2016.00043","article-title":"Glycemic control with ipragliflozin, a novel selective SGLT2 inhibitor, ameliorated endothelial dysfunction in streptozotocin-induced diabetic mouse","volume":"3","author":"Salim","year":"2016","journal-title":"Front Cardiovasc Med"},{"issue":"12","key":"10.1016\/j.jphs.2021.08.010_bib14","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.2337\/dc18-1087","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study","volume":"41","author":"Dandona","year":"2018","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.jphs.2021.08.010_bib15","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/dom.13922","article-title":"Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT-5): 52-week results from a randomized, open-label, phase III clinical trial","volume":"22","author":"Araki","year":"2020","journal-title":"Diabetes Obes Metabol"},{"issue":"17","key":"10.1016\/j.jphs.2021.08.010_bib16","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1007\/s40265-019-01213-x","article-title":"Dapagliflozin: a review in type 1 diabetes","volume":"79","author":"Paik","year":"2019","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.jphs.2021.08.010_bib17","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1007\/s00125-018-4671-6","article-title":"SGLT inhibitor adjunct therapy in type 1 diabetes","volume":"61","author":"McCrimmon","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.jphs.2021.08.010_bib18","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s00125-003-1193-6","article-title":"Leptin as an adjunct of insulin therapy in insulin-deficient diabetes","volume":"46","author":"Miyanaga","year":"2003","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.jphs.2021.08.010_bib19","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1007\/s00125-016-3898-3","article-title":"The role of leptin in diabetes: metabolic effects","volume":"59","author":"Meek","year":"2016","journal-title":"Diabetologia"},{"issue":"7702","key":"10.1016\/j.jphs.2021.08.010_bib20","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41586-018-0049-7","article-title":"Genetic identification of leptin neural circuits in energy and glucose homeostases","volume":"556","author":"Xu","year":"2018","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.jphs.2021.08.010_bib21","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.cmet.2013.08.004","article-title":"Leptin engages a hypothalamic neurocircuitry to permit survival in the absence of insulin","volume":"18","author":"Fujikawa","year":"2013","journal-title":"Cell Metabol"},{"issue":"5","key":"10.1016\/j.jphs.2021.08.010_bib22","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.2337\/db10-0958","article-title":"Leptin therapy reverses hyperglycemia in mice with streptozotocin-induced diabetes, independent of hepatic leptin signaling","volume":"60","author":"Denroche","year":"2011","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.jphs.2021.08.010_bib23","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1172\/JCI88477","article-title":"Mechanism for leptin's acute insulin-independent effect to reverse diabetic ketoacidosis","volume":"127","author":"Perry","year":"2017","journal-title":"J\u00a0Clin Invest"},{"issue":"5","key":"10.1016\/j.jphs.2021.08.010_bib24","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2337\/dc16-1553","article-title":"Efficacy and safety of metreleptin therapy in patients with type 1 diabetes: a pilot study","volume":"40","author":"Vasandani","year":"2017","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.jphs.2021.08.010_bib25","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1254\/jphs.12089FP","article-title":"Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice","volume":"120","author":"Tahara","year":"2012","journal-title":"J\u00a0Pharmacol Sci"},{"issue":"5","key":"10.1016\/j.jphs.2021.08.010_bib26","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1007\/s00125-015-3529-4","article-title":"Leptin induces fasting hypoglycaemia in a mouse model of diabetes through the depletion of glycerol","volume":"58","author":"Denroche","year":"2015","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.jphs.2021.08.010_bib27","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1210\/en.2015-1890","article-title":"Insulin knockout mice have extended survival but volatile blood glucose levels on leptin therapy","volume":"157","author":"Neumann","year":"2016","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.jphs.2021.08.010_bib28","doi-asserted-by":"crossref","first-page":"25465","DOI":"10.1038\/srep25465","article-title":"Evaluation of the appropriateness of using glucometers for measuring the blood glucose levels in mice","volume":"6","author":"Togashi","year":"2016","journal-title":"Sci Rep"},{"issue":"43","key":"10.1016\/j.jphs.2021.08.010_bib29","doi-asserted-by":"crossref","first-page":"17166","DOI":"10.1523\/JNEUROSCI.0897-13.2013","article-title":"GABA type B receptor signaling in proopiomelanocortin neurons protects against obesity, insulin resistance, and hypothalamic inflammation in male mice on a high-fat diet","volume":"33","author":"Ito","year":"2013","journal-title":"J\u00a0Neurosci"},{"issue":"40","key":"10.1016\/j.jphs.2021.08.010_bib30","doi-asserted-by":"crossref","first-page":"17391","DOI":"10.1073\/pnas.1008025107","article-title":"Leptin therapy improves insulin-deficient type 1 diabetes by CNS-dependent mechanisms in mice","volume":"107","author":"Fujikawa","year":"2010","journal-title":"Proc Natl Acad Sci Unit States Am"},{"issue":"5","key":"10.1016\/j.jphs.2021.08.010_bib31","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00125-016-3909-4","article-title":"Pleotropic effects of leptin to reverse insulin resistance and diabetic ketoacidosis","volume":"59","author":"Perry","year":"2016","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.jphs.2021.08.010_bib32","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.diabet.2012.03.001","article-title":"Metabolic dysfunction in late-puberty adolescent girls with type 1 diabetes: relationship to physical activity and dietary intakes","volume":"38","author":"Heyman","year":"2012","journal-title":"Diabetes Metab"},{"issue":"8","key":"10.1016\/j.jphs.2021.08.010_bib33","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.molmet.2016.06.009","article-title":"The role of autonomic efferents and uncoupling protein 1 in the glucose-lowering effect of leptin therapy","volume":"5","author":"Denroche","year":"2016","journal-title":"Mol Metab"},{"issue":"3","key":"10.1016\/j.jphs.2021.08.010_bib34","doi-asserted-by":"crossref","first-page":"150756","DOI":"10.1371\/journal.pone.0150756","article-title":"Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, acutely reduces energy expenditure in BAT via neural signals in mice","volume":"11","author":"Chiba","year":"2016","journal-title":"PloS One"},{"issue":"12","key":"10.1016\/j.jphs.2021.08.010_bib35","doi-asserted-by":"crossref","first-page":"28311","DOI":"10.1371\/journal.pone.0028311","article-title":"A\u00a0cross-sectional characterization of insulin resistance by phenotype and insulin clamp in East Asian Americans with type 1 and type 2 diabetes","volume":"6","author":"Hsu","year":"2011","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.jphs.2021.08.010_bib36","doi-asserted-by":"crossref","first-page":"647","DOI":"10.33549\/physiolres.931995","article-title":"Gut peptide hormones and pediatric type 1 diabetes mellitus","volume":"60","author":"Huml","year":"2011","journal-title":"Physiol Res"},{"key":"10.1016\/j.jphs.2021.08.010_bib37","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.jphs.2021.08.010_bib38","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jdiacomp.2014.10.001","article-title":"Long-acting hypoglycemic effects of PEGylated FGF21 and insulin glargine in mice with type 1 diabetes","volume":"29","author":"Xu","year":"2015","journal-title":"J\u00a0Diabet Complicat"},{"issue":"2","key":"10.1016\/j.jphs.2021.08.010_bib39","doi-asserted-by":"crossref","first-page":"220","DOI":"10.4158\/EP15869.RA","article-title":"The emerging role of adjunctive noninsulin antihyperglycemic therapy in the management of type 1 diabetes","volume":"22","author":"Bode","year":"2016","journal-title":"Endocr Pract"},{"issue":"6","key":"10.1016\/j.jphs.2021.08.010_bib40","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2337\/dc15-0078","article-title":"Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D exchange clinic registry","volume":"38","author":"Miller","year":"2015","journal-title":"Diabetes Care"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861321000852?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861321000852?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T20:01:34Z","timestamp":1761163294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347861321000852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S1347861321000852"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2021.08.010","relation":{},"ISSN":["1347-8613"],"issn-type":[{"type":"print","value":"1347-8613"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peripheral combination treatment of leptin and an SGLT2 inhibitor improved glucose metabolism in insulin-dependent diabetes mellitus mice","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2021.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}